Connect with us

Business

After Pfizer and Modena, AstraZeneca announced the effectiveness of the Covid vaccine: an average of 70% between the two options

Published

on

AstraZeneca announced the effectiveness of the Covid vaccine

On November 23, the British pharmaceutical company AstraZeneca announced that an interim analysis based on clinical trials in the UK and Brazil showed that the candidate vaccine AZD1222 developed in cooperation with the University of Oxford has average effectiveness of 70% in preventing the new coronavirus. The vaccine is 90% effective in the smaller dose regimen, and 62% in the full-dose regimen.

Earlier this month, US companies Pfizer and Moderna announced that their vaccine candidates were more than 90% effective.

In September of this year, AstraZeneca once halted the third global clinical trial of the AZD1222 vaccine due to “severe side effects” in a patient. The following month, another heart-wrenching event occurred in the AstraZeneca vaccine trial: a Brazilian volunteer died, but it is not clear whether the volunteer received the vaccine or a placebo. After a series of twists and turns, AstraZeneca said this time that no serious safety incidents related to the vaccine have been found.

British Health Minister Hancock said that the news that AstraZeneca’s vaccine is 90% effective is “encouraging” and they have ordered 100 million doses. British Prime Minister Johnson also said that this is “exciting” news.

AstraZeneca announced the effectiveness of the Covid vaccine

 

“Cold storage for 6 months” “Capable of producing 3 billion doses in 2021”.

AstraZeneca said on the 23rd that according to the independent data security monitoring committee, the effectiveness of the company’s AZD1222 vaccine has reached its main goal. It can prevent the new coronavirus 14 days or more after two doses of the vaccine. Serious vaccine-related safety incidents.

According to AstraZeneca, the company’s AZD1222 vaccine’s average effectiveness of 70% data is based on two vaccination programs. A vaccination scheme shows that when the AZD1222 vaccine is vaccinated in half dose, the full dose is vaccinated at least one month apart, and the effectiveness is 90%. Another vaccination scheme showed that the effectiveness of two full-dose vaccination at least one month apart was 62%.

The effectiveness analysis of AstraZeneca is based on data from the UK Phase II/III clinical trials and Brazil Phase III clinical trials. A total of 23,000 people from these two countries participated in the trial, including 131 people infected with the new coronavirus. AstraZeneca said that their clinical trials are also conducted in the United States, Japan, Russia, and other countries, with as many as 60,000 participants worldwide.

It is worth noting that AstraZeneca claims that the AZD1222 vaccine can be stored and transported under refrigerated conditions (2 to 8 degrees Celsius / 36 to 46 degrees Fahrenheit) for at least 6 months. In contrast, the US-based Modena vaccine candidate can only be stored at refrigerated temperatures for 30 days and can be stored at minus 4 degrees Fahrenheit (about minus 20 degrees Celsius) for at least 6 months. And Pfizer’s vaccine storage is even more “hard”. Its vaccine can be stored for 15 days at around minus 94 degrees Fahrenheit (about minus 70 degrees Celsius). After leaving this environment, Pfizer vaccines can only be stored for up to 5 days at refrigerated temperatures.

AstraZeneca is very confident in its own vaccines, saying that it is seeking relevant approvals from regulatory agencies in various countries, and said that its production capacity will reach 3 billion doses in 2021.

“These findings show that we already have an effective vaccine to save many lives. What is exciting is that we found that one of the vaccination programs can reach 90% effectiveness.” Andrew Pola, chief researcher of the AZD1222 vaccine clinical trial Professor Andrew Pollard said.

As foreign companies successively announced the effectiveness of their new coronavirus vaccine candidates, Zhong Nanshan, an academician of the Chinese Academy of Engineering, pointed out on the 16th of this month that foreign Pfizer vaccines can prevent 90% of infections. In fact, the research and development of vaccines in Guangdong, and even China is at the same level, but there is The results of the first phase can only be announced. Zhong Nanshan hopes that in the future, in the field of biomedicine, basic research, clinical research, and industrialization can be more closely integrated to form a better mechanism.

 

European stock markets are boosted.

After the AstraZeneca test data was released, British Health Minister Hancock and Prime Minister Johnson sent “congratulatory messages” one after another.

According to the British “Sky News” report on the 23rd, Hancock said that the news of the Oxford University and AstraZeneca vaccines is “encouraging”, and data shows that their vaccines can reach 90% effectiveness at the right dose.

Hancock said that the British Ministry of Health has ordered 100 million doses of the AstraZeneca vaccine. He also specifically mentioned that AstraZeneca vaccines are easier to manage than Pfizer vaccines because the storage conditions of the former do not need to be minus 70 degrees Celsius. “This is really good news.”

Johnson also said, “The trial proved that the Oxford vaccine is so effective. This is incredible and exciting news. Although there are further safety checks, these are excellent results. Thanks to Oxford University and AstraZeneca Pharmaceuticals. Outstanding scientists, and all volunteers participating in the experiment.”

News of the effectiveness of AstraZeneca’s vaccine does not appear to be reflected in the company’s stock price. Earlier, when Pfizer said its new coronavirus vaccine could prevent 90% of infections, the company’s stock price rose by 15%, and the three major US stock indexes also reached historical highs. But so far, AstraZeneca’s US stocks have fallen nearly 0.9% before the market.

Continue Reading
Advertisement
Click to comment
Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Business

California Disney refunds annual card users, and Paris Disney’s re-opening date is delayed by 48 days

Published

on

Recently, according to information released by the Disney Company, Ken Potrock, President of Disneyland Resort (California Disney Resort), said in a statement that due to the ongoing uncertainty of the new coronavirus epidemic and the false news of the reopening of the California Disney Resort, Appropriate refunds will be made for eligible California Disney Resort annual card users, and the current (annual card) plan will be canceled.

It can be seen that due to the impact of the US epidemic, the California Disney Resort has been unable to reopen for a long time. Prior to this, California Disneyland has been “working hard” for the reopening.

On October 21st last year, Disneyland in California announced through the Disney Company: “We have proven that we can responsibly reopen under the science-based health and safety measures that are strictly enforced in theme parks around the world. However. , California continues to ignore this fact and instead requires the state government to know the guidelines that do not work. This makes the standards we meet very different from those of other reopened businesses and state-run facilities. We hope that, together with the union, Let people return to work, but these state government guidelines will keep us closed for the foreseeable future, forcing thousands of people to lose their jobs, cause small family businesses to inevitably close down, and cause damage to Southern California communities Irreparable destruction.”

But in the comments on the news on Twitter, most people believed that under the current conditions, the park should not be reopened.

Up to now, of the six Disney parks in the world, only Shanghai Disneyland, Tokyo Disneyland, and Orlando Disneyland in the United States are open. In addition to Disneyland in California, Hong Kong Disneyland and Disneyland Paris are also closed.

On December 1, 2020, Hong Kong Disneyland Resort announced that in response to the government’s request and in line with the current epidemic prevention measures taken by Hong Kong, Hong Kong Disneyland will be temporarily closed from December 2. Hong Kong Disneyland Resort will maintain close contact with the Hong Kong government and health authorities and will announce the reopening date depending on the situation. This is the third time Hong Kong Disneyland has closed the park since the outbreak of the new coronavirus in 2020.

In addition, Disneyland Paris has also been closed twice.

On October 29, 2020, Disneyland Paris has closed again after reopening on July 15. According to news from the official website of Disneyland Paris, in order to celebrate the Christmas holiday, Disneyland Paris will accept reservations from December 19, 2020, to January 3, 2021, and hopes to open it according to the prevailing situation and government guidance. From January 4th to February 12th, Disneyland Paris will be closed.

But for now, Disney Paris may not be able to reopen as scheduled on February 13.

On January 18th, local time in France, the updated message of Disneyland Paris said: “If conditions permit, we will reopen Disneyland Paris on April 2, 2021, and accept reservations from that date.”

Continue Reading

Business

Many European countries shortage of vaccines and French companies may manufacture rival’s vaccines

About a third of the European Union member states are currently in short supply of the new coronavirus vaccine. Six EU member states sent a letter to the European Commission on the 15th, requesting the European Commission to put pressure on vaccine manufacturers to ensure timely, stable, and transparent delivery of vaccines.

Published

on

About a third of the European Union member states are currently in short supply of the new coronavirus vaccine. Six EU member states sent a letter to the European Commission on the 15th, requesting the European Commission to put pressure on vaccine manufacturers to ensure timely, stable, and transparent delivery of vaccines.

French government officials said on the same day that the Sanofi Group, the largest French pharmaceutical company, may produce the new coronavirus vaccine developed by foreign pharmaceutical companies.

 

Complaining about insufficient supply

The new coronavirus vaccine jointly developed by Pfizer Pharmaceuticals and German Biotech will be vaccinated in the EU on a large scale from December 27, 2020. The health ministers of EU member states held a video conference on the 13th of this month to discuss vaccine delivery. A participant told Reuters that about one-third of EU member states complained of insufficient vaccine supplies.

Sweden, Denmark, Finland, Lithuania, Latvia, and Estonia sent a letter to the European Commission on the 15th, requesting the European Commission to put pressure on Pfizer and new biotech companies to ensure timely, stable, and transparent vaccine delivery.

The health ministers of the aforementioned six countries said in the letter: “This situation is unacceptable…not only affects the established vaccination schedule but also undermines the credibility of the vaccination plan.”

The Danish Minister of Health Magnus Hojnik said: “We are racing against the new coronavirus and the more contagious mutant virus… We, therefore, attach great importance to the reduction in vaccine deliveries.”

According to the Finnish Broadcasting Corporation News Department, the delay in vaccine supply will cause difficulties in the distribution of vaccines in Finland between the end of January and the beginning of February.

Italian Covid-19 Emergency Committee Commissioner Domenico Alcuri said that Pfizer will cut the dose of vaccine delivered to Italy by 29% starting on the 18th. The pharmaceutical company did not specify how long the supply reduction will last.

 

Preparing to increase production

Pfizer said on the 15th that in order to achieve the goal of increasing vaccine production, the company has changed its production process, which will “temporarily affect” the vaccine delivery schedule from the end of January to the beginning of February. The German Biotech Company said that the output of the company’s plant in the town of Pierce, Belgium will decline in the next few weeks. The reason for the decrease in output is that the company has changed some production processes to increase production capacity.

The vaccine factory in Pierce Township supplies vaccines to countries and regions outside the United States.

The European Commission, on behalf of EU member states, negotiated vaccine procurement with Pfizer and German Biotech, but it is not responsible for vaccine delivery. According to the contract, Pfizer and German Biotech will supply 600 million doses of vaccine to the EU. The two pharmaceutical companies agreed to deliver 75 million doses of vaccine to the EU in the second quarter of this year or later, but neither mentioned how many vaccines will be delivered in the first quarter of this year.

European Commission President Ursula von der Lein said that she had already had a phone call with Pfizer CEO Albert Bla. Bra “reassured that all vaccines promised to be delivered in the first quarter will be delivered in the first quarter. He personally asked, and will shorten the time for delayed delivery to ensure that they can catch up as soon as possible.”

The population of the EU is approximately 450 million. Two doses of this vaccine are required.

 

Possible to cooperate to increase capacity

In an interview with the media on the 15th, Agnès Panier-Lunache, the ministerial representative of the French economic department in charge of industry, said that the new coronavirus vaccine developed by Sanofi Group, France’s largest pharmaceutical company, will take time to be available. This company may Assist in the production of new coronavirus vaccines developed by other national pharmaceutical companies.

Panier-Lunache said that she discussed the possibility of Sanofi as a subcontractor for other pharmaceutical companies with Sanofi Group. “We are working with them (Sanofi) to consider… They are working with German Biotech and (U.S.) Janssen Pharmaceuticals separately to study whether (cooperation) is possible.”

According to her, the main issue for cooperative production is whether Sanofi has spare capacity to produce vaccines in the next three to five months.

Sanofi Group told Agence France-Presse that Sanofi is evaluating the technical feasibility of temporarily producing vaccines for other pharmaceutical companies, and the discussion is still at a “very early stage.” Sanofi did not mention which companies it cooperates with.

Agence France-Presse reported that a French pharmaceutical subcontractor said it would produce Pfizer-Germany’s new biotechnology vaccine, and another pharmaceutical subcontractor is scheduled to start producing the new coronavirus vaccine developed by Modena in the United States at the end of February or early March.

Continue Reading

Business

WeWork CEO expects profit in the fourth quarter of this year and plans to re-IPO

Published

on

WeWork global CEO Sandeep Mathrani said on January 14 that WeWork is expected to achieve profitability in the fourth quarter of this year. After achieving profitability, the IPO plan will be put on the agenda.

Mathrani said that WeWork currently has $3 billion in liquid assets on its books, enough to support the company until 2022. He said that in December 2020, WeWork announced the best member sales data since December 2019. Mathrani seems to want to hint that the company has a bright future.

Regarding the Chinese business, Mathrani said that from the perspective of occupancy rate, leasing, and demand, China’s office space usage has basically returned to 90% of the level before the new coronavirus epidemic.

The controlling stake in WeWork’s China business was announced in September 2020. At that time, WeWork announced that its existing investor in its Chinese subsidiary, Zhixin Capital, had injected an additional US$200 million in the capital and now owns more than half of its Chinese business. Michael Jiang, operating partner of Trustworthy Capital and former senior vice president of Meituan Dianping, will serve as the acting CEO of WeWork China. This means that WeWork China must implement a comprehensive localized operation model.

It is worth noting that although WeWork’s parent company, We Company, has given up its operational control over WeWork China, it will continue to receive annual service fees; in exchange, WeWork’s business in China will continue to use WeWork’s brand and services. Part of the transaction is similar to the traditional franchise model. According to people familiar with the matter, WeWork will retain a minority stake in the Chinese business and a board seat.

This company, once known as the American unicorn, experienced IPO abortion, plummeting company valuation, layoffs, replacement of founders, major shareholders investing large sums of money to continue their lives, appointing new CEOs, etc. from 2019 to 2020. A series of actions tried to save the originator of this shared office space.

As the majority shareholder of WeWork, SoftBank Group planned to acquire WeWork shares worth up to 3 billion US dollars at a price of 19.19 US dollars per share in November 2019, including the company’s co-founder and former CEO Adam Neumann up to 970 million US dollars Of shares. But in the end, SoftBank decided to abandon its US$3 billion tender offer for WeWork.

Continue Reading

Trending